Send the following on WhatsApp
Continue to Chathttps://de.marketscreener.com/kurs/aktie/MORPHOSYS-AG-436425/news/MorphoSys-und-I-Mab-geben-die-Dosierung-des-ersten-Patienten-in-der-Phase-1-Studie-mit-MOR210-TJ21-32271563/?utm_source=whatsapp&utm_medium=social&utm_campaign=share